healthprotocol.wiki

vanderzouwen_2023_cohort_feasibility-safety-efficacy-early-prophylactic-dli-tcd-allosct-acute-leukemia

5 findings

Protocol
therapy-stem-cell-transplant-allogeneic-t-cell-depleted-early-prophylactic-dli-high-risk-leukemia-matched-sibling-donor
Outcome
immune-graft-versus-host-disease-moderate-to-severe-cumulative-incidence-between-3-and-6-months
n
13
effect
-6
attribution
40
Protocol
therapy-stem-cell-transplant-allogeneic-t-cell-depleted-early-prophylactic-dli-high-risk-leukemia-ric-matched-sibling-donor
Outcome
immune-graft-versus-host-disease-moderate-to-severe-cumulative-incidence-between-3-and-6-months
n
4
effect
6
attribution
25
Protocol
therapy-stem-cell-transplant-allogeneic-t-cell-depleted-early-prophylactic-dli-high-risk-leukemia-ric-unrelated-donor
Outcome
immune-graft-versus-host-disease-moderate-to-severe-cumulative-incidence-between-3-and-6-months
n
12
effect
-42
attribution
50
Protocol
therapy-stem-cell-transplant-allogeneic-t-cell-depleted-early-prophylactic-dli-high-risk-leukemia-unrelated-donor
Outcome
immune-graft-versus-host-disease-moderate-to-severe-cumulative-incidence-between-3-and-6-months
n
13
effect
5
attribution
35
Protocol
therapy-stem-cell-transplant-allogeneic-t-cell-depleted-early-prophylactic-donor-lymphocyte-infusion-high-risk-acute-leukemia
Outcome
immune-graft-versus-host-disease-moderate-to-severe-cumulative-incidence-between-3-and-6-months
n
42
effect
-20
attribution
45